Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2005-06-28
2010-10-05
Chong, Kimberly (Department: 1635)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C536S024310, C536S024100, C436S006000, C436S169000, C436S169000, C514S04400A
Reexamination Certificate
active
07807816
ABSTRACT:
Antisense molecules capable of binding to a selected target site in the dystrophin gene to induce exon skipping are described.
REFERENCES:
patent: 5149797 (1992-09-01), Pederson et al.
patent: 6784291 (2004-08-01), Iversen et al.
patent: 780517 (2001-11-01), None
patent: 2003284638 (2004-07-01), None
patent: 1191097 (2002-03-01), None
patent: 9730067 (1997-08-01), None
patent: WO 02/024906 (2002-03-01), None
patent: 2004083446 (2004-09-01), None
patent: WO 2004/083432 (2004-09-01), None
van Deutekom et al. Advances in Ducchenne muscular dystrophy gene therapy. Nature Reviews vol. 4, Oct. 2003.
Abbs et al., “A convenient multiplex PCR system for the detection of dystrophin gene deletions: a comparative analysis with cDNA hybridisation shows mistypings by both methods,”J. Med Genet 28:304-311, 1991.
Dirksen et al., “Mapping the SF2/ASF Binding Sites in the Bovine Growth Hormone Exonic Splicing Enhancer,”The Journal of Biological Chemistry 275(37):29170-29177, 2000.
Hussey et al., “Analysis of five Duchenne muscular dystrophy exons and gender determination using conventional duplex polymerase chain reaction on single cells,”Molecular Human Reproduction 5(11):1089-1094, 1999.
Karras et al., “Deletion of Individual Exons and Induction of Soluble Murine Interleukin-5 Receptor-α Chain Expression through Antisense Oligonucleotide-Mediated Redirection of Pre-mRNA Splicing,”Molecular Pharmacology 58:380-387, 2000.
Liu et al., “Identification of functional exonic splicing enhancer motifs recognized by individual SR proteins,”Genes&Development 12:1998-2012, 1998.
Matsuo, “Duchenne/Becker muscular dystrophy: from molecular diagnosis to gene therapy,”Brain&Development 18:167-172, 1996.
Monaco et al., “An Explanation for the Phenotypic Differences between Patients Bearing Partial Deletions of the DMD Locus,”Genomics 2:90-95, 1988.
Pramono et al., “Induction of Exon Skipping of the Dystrophin Transcript in Lymphoblastoid Cells by Transfecting an Antisense Oligodeoxynucleotide Complementary to an Exon Recognition Sequence,”Biochemical and Biophysical Research Communications 226:445-449, 1996.
Roberts et al., “Exon Structure of the Human Dystrophin Gene,”Genomics 16:536-538, 1993.
Shapiro et al., “RNA splice junctions of different classes of eukaryotes: sequence statistics and functional implications in gene expression,”Nucleic Acids Research 15(17):7155-7174, 1987.
Sherratt et al., “Exon Skipping and Translation in Patients with Frameshift Deletions in the Dystrophin Gene,”Am. J. Hum. Genet. 53:1007-1015, 1993.
Shiga et al., “Disruption of the Splicing Enhancer Sequence within Exon 27 of the Dystrophin Gene by a Nonsense Mutation Induces Partial Skipping of the Exon and Is Responsible for Becker Muscular Dystrophy,”J. Clin. Invest. 100(9):2204-2210, 1997.
Tanaka et al., “Polypurine Sequences within a Downstream Exon Function as a Splicing Enhancer,”Molecular and Cellular Biology 14(2):1347-1354, 1994.
Thanh et al., “Characterization of Revertant Muscle Fibers in Duchenne Muscular Dystrophy, Using Exon-Specific Monoclonal Antibodies against Dystrophin,”Am. J. Hum. Genet. 56:725-731, 1995.
Watakabe et al., “The role of exon sequences in splice site selection,”Genes Dev. 7:407-418, 1993.
Aartsma-Rus et al., Targeted exon skipping as a potential gene correction therapy for Duchenne muscular dystrophy, Neuromuscular Disorders 12:571-577 (2002).
Aartsma-Rus et al., Therapeutic antisense-induces exon skipping in cultured muscle cells from six different DMD patients, Human Molecular Genetics 12(8):907-914 (2003).
Aartsma-Rus et al., Antisense-Induced Multiexon Skipping for Duchenne Muscular Dystrophy Makes More Sense, Am. J. Hum. Genet. 74:83-92 (2004).
Deangelis et al., Chimeric snRNA molecules carrying antisense sequences against the splice junctions of exon51 of the dystophin pe-mRNA induce exon skipping and resoration of a dystophin synthesis in Δ48-50 DMD cells, PNAS 99(14):9456-9461 (2002).
Dunckley et al., Modification of splicing in the dystophin gene in cultureMdxmuscle cells by antisense oligoribonucleotides, Human Molecular Genetics 5(1):1083-1090 (1995).
Dunckley et al., Modulation of Splicing in theDMDGene by Antisense Oligoribunucleotides, Nucleosides & Nucleotides 16:1665-1668 (1997).
Errington et al., Target section for antisense oligonucleotide induced exon skipping in the dystrophin gene, J. Gen. Med. 5:518-527 (2003).
Gebski et al., Morpholino antisense oligonucleotide induced dystrophin exon 23 skipping inmdxmouse muscle, Human Molecular Genetics 12(15):1801-1812 (2003).
Lu et al., Functional amounts of dystophin produced by skipping the mutated exon in themdxdystrophic mouse, Nature Medicine 9(8):10091014 (2003).
Mann et al., Antisense-induced exon skipping and synthesis of dystrophin in themdxmouse, PNAS 98:42-47 (2001).
Mann et al., Improved antisense oligonucleotide induced exon skipping in themdxmouse model of muscular dystrophy, J. Gen. Med. 4:644-654 (2002).
Matsuo et al., Exon Skipping during Spicking of Dystrophin mRNA Precursor due to an Intraeson Deletion in the Dystrophin Gene of Duchenne Muscular Dystrophy Kobe, J. Clin. Invest. 87:2127-2131 (1991).
Sierakowska et al., Repair of thalassemic human β-globin mRNA in mammalian cells by antisense oligonucleotides, PNAS 93:12840-12844 (1996).
Takeshima et al., Modulation of in Vitro Splicing of the Upstream Intron by Modifying an Intra-Exon Sequence Which is Deleted from the Dystrophin Gene in Dystrophin Kobe, J. Clin. Invest. 95:515-520 (1995).
Van Deutekom et al., Antisense-induced exon skipping restores dystrophin expression in DMD patient derived muscle cells, Human Molecular Genetics 10(15):1547-1554 (2001).
Wilton et al., Specific removal of the nonsense mutation from themdxdystophin mRNA using antisense oligonucleotides, Neuromuscular Disorders 9:330-338 (1999).
Fletcher Sue
McClorey Graham
Wilton Stephen Donald
Chong Kimberly
Seed IP Law Group PLLC
University of Western Australia
LandOfFree
Antisense oligonucleotides for inducing exon skipping and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antisense oligonucleotides for inducing exon skipping and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antisense oligonucleotides for inducing exon skipping and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4240715